Overview

A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures when compared to adjunctive treatment with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Pharma
Treatments:
Etiracetam
Levetiracetam
Pharmaceutical Solutions
Piracetam